These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 37087895)

  • 1. Discovery of ML210-Based glutathione peroxidase 4 (GPX4) degrader inducing ferroptosis of human cancer cells.
    Wang H; Wang C; Li B; Zheng C; Liu G; Liu Z; Zhang L; Xu P
    Eur J Med Chem; 2023 Jun; 254():115343. PubMed ID: 37087895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A potent GPX4 degrader to induce ferroptosis in HT1080 cells.
    Song H; Liang J; Guo Y; Liu Y; Sa K; Yan G; Xu W; Xu W; Chen L; Li H
    Eur J Med Chem; 2024 Feb; 265():116110. PubMed ID: 38194774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis, and Biological Evaluation of Hydrophobic-Tagged Glutathione Peroxidase 4 (GPX4) Degraders.
    Li X; Hu M; Zhang Y; Hua H; Sun Y; Xiang Q; Zhu D
    Bioorg Chem; 2024 Mar; 144():107115. PubMed ID: 38232684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual degradation mechanism of GPX4 degrader in induction of ferroptosis exerting anti-resistant tumor effect.
    Wang C; Zheng C; Wang H; Shui S; Jin H; Liu G; Xu F; Liu Z; Zhang L; Sun D; Xu P
    Eur J Med Chem; 2023 Feb; 247():115072. PubMed ID: 36603510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and optimization of indirubin derivatives as novel ferroptosis inducers for the treatment of colon cancer.
    Zhu JM; Chen C; Kong M; Zhu L; Li YL; Zhang JF; Yu ZP; Xu SS; Kong LY; Luo JG
    Eur J Med Chem; 2023 Dec; 261():115829. PubMed ID: 37801824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospects for Anti-Tumor Mechanism and Potential Clinical Application Based on Glutathione Peroxidase 4 Mediated Ferroptosis.
    Chen M; Shi Z; Sun Y; Ning H; Gu X; Zhang L
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of glutathione peroxidase 4 and intracellular iron level in ovarian cancer cells-"utilization" of ferroptosis mechanism.
    Li D; Zhang M; Chao H
    Inflamm Res; 2021 Dec; 70(10-12):1177-1189. PubMed ID: 34537856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological evaluation of RSL3-based GPX4 degraders with hydrophobic tags.
    Ning Y; Zhu Z; Wang Y; Fan X; Wang J; Qian H; Qiu X; Wang Y
    Eur J Med Chem; 2024 Nov; 277():116719. PubMed ID: 39094276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationship study of RSL3-based GPX4 degraders and its potential noncovalent optimization.
    Zheng C; Wang C; Sun D; Wang H; Li B; Liu G; Liu Z; Zhang L; Xu P
    Eur J Med Chem; 2023 Jul; 255():115393. PubMed ID: 37098297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular Delivery of Glutathione Peroxidase Degrader Induces Ferroptosis In Vivo.
    Luo T; Zheng Q; Shao L; Ma T; Mao L; Wang M
    Angew Chem Int Ed Engl; 2022 Sep; 61(39):e202206277. PubMed ID: 35924720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of proteolysis-targeting chimeras (PROTACs) as degraders of glutathione peroxidase 4.
    Cai M; Ma F; Hu C; Li H; Cao F; Li Y; Dong J; Qin JJ
    Bioorg Med Chem; 2023 Jul; 90():117352. PubMed ID: 37257255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting GPX4 in human cancer: Implications of ferroptosis induction for tackling cancer resilience.
    Lee J; Roh JL
    Cancer Lett; 2023 Apr; 559():216119. PubMed ID: 36893895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ZX703: A Small-Molecule Degrader of GPX4 Inducing Ferroptosis in Human Cancer Cells.
    Hu M; Li X; Wang L; Zhang Y; Sun Y; Hua H; Liu H; Cai T; Zhu D; Xiang Q
    ACS Med Chem Lett; 2024 Mar; 15(3):406-412. PubMed ID: 38505849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent nanoreactor-mediated ferroptosis-based strategy for the reversal of cancer chemoresistance to Sorafenib.
    Wang X; Zhao L; Wang C; Wang L; Wu H; Song X; Wang W; Xu H; Dong X
    Acta Biomater; 2023 Mar; 159():237-246. PubMed ID: 36736851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Novel Potent Covalent Glutathione Peroxidase 4 Inhibitors as Highly Selective Ferroptosis Inducers for the Treatment of Triple-Negative Breast Cancer.
    Chen T; Leng J; Tan J; Zhao Y; Xie S; Zhao S; Yan X; Zhu L; Luo J; Kong L; Yin Y
    J Med Chem; 2023 Jul; 66(14):10036-10059. PubMed ID: 37452764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-Elemene induced ferroptosis via TFEB-mediated GPX4 degradation in EGFR wide-type non-small cell lung cancer.
    Zhao LP; Wang HJ; Hu D; Hu JH; Guan ZR; Yu LH; Jiang YP; Tang XQ; Zhou ZH; Xie T; Lou JS
    J Adv Res; 2024 Aug; 62():257-272. PubMed ID: 37689240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ferroptosis inducing compounds RSL3 and ML162 are not direct inhibitors of GPX4 but of TXNRD1.
    Cheff DM; Huang C; Scholzen KC; Gencheva R; Ronzetti MH; Cheng Q; Hall MD; Arnér ESJ
    Redox Biol; 2023 Jun; 62():102703. PubMed ID: 37087975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dauricine alleviated secondary brain injury after intracerebral hemorrhage by upregulating GPX4 expression and inhibiting ferroptosis of nerve cells.
    Peng C; Fu X; Wang K; Chen L; Luo B; Huang N; Luo Y; Chen W
    Eur J Pharmacol; 2022 Jan; 914():174461. PubMed ID: 34469757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GPX4: The hub of lipid oxidation, ferroptosis, disease and treatment.
    Liu Y; Wan Y; Jiang Y; Zhang L; Cheng W
    Biochim Biophys Acta Rev Cancer; 2023 May; 1878(3):188890. PubMed ID: 37001616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid Peroxidation-Dependent Cell Death Regulated by GPx4 and Ferroptosis.
    Imai H; Matsuoka M; Kumagai T; Sakamoto T; Koumura T
    Curr Top Microbiol Immunol; 2017; 403():143-170. PubMed ID: 28204974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.